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Table. Percentages of pts and Two-Year Rates of NRM and OS in
the Validation Set (n  346) as Scored by the New HCT-Speciﬁc
Comorbidity Index Compared to the Original CCI
HCT-CI pts, %
Two-Year Rate
Original CCI pts, %
Two-Year Rate
NRM, % OS, % NRM, % OS, %
0–1 37 13 72 0 58 17 64
2–3 36 22 58 1 27 33 51
>4 27 40 35 >2 15 31 41
NRM indicates non-relapse mortality; OS, overall survival; CCI,
Charlson comorbidity index; and HCT-CI, hematopoietic cell
transplantation-speciﬁc comorbidity index.
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EFFECTS OF NATURAL KILLER (NK) CELLS ON ALLOGENEIC BONE
MARROW TRANSPLANTATION (BMT) IN FETAL AND NEWBORN MICE
Bhattacharyya, S.; Cowan, M.J. UCSF Children’s Hospital, San Fran-
cisco, CA.
NK cells are capable of receptor-mediated lysis of target cells that
lack self class I MHC molecules. Thus, it is possible that they can be
used effectively in an MHC I mismatched allogeneic BMT to create
myeloablation without developing GVHD. We wanted to deﬁne the
role of the NK cell as a myeloablative agent. C57Bl/6 (B6) adult NK
cells were injected i.p. into 2 day old Balb/c newborns. At various
times post transplant, bone marrow was harvested and in-vitro colony
forming assays were done. We found that allogeneic NK cells de-
stroyed both erythroid and myeloid progenitor cells by 5 days post
injection with some recovery by 19 days. We then injected NK cells
with/without bone marrow from C57Bl/6 (B6) mice into 14 day old
Balb/c fetuses and newborn animals. We found that none of the fetal
recipients survived the in utero transplants even when the number of
NK cells was reduced to 10,000 cells. Histologic studies suggested
severe liver toxicity associated with the fetal injections. In contrast,
7/10 newborn recipients of allogeneic lin BM and NK cells had
multi-lineage engraftment 8 weeks post transplant (Table). The en-
graftment was inhibited by co-administration of anti NK1.1 mAb or
anti-TGF beta antibody suggesting that NK cells play a role in the
engraftment and mediate their effect at least partially through the
secretion of TGF-beta. We used an Artemis deﬁcient TBNK
mouse to study the repopulation of the marrow following transplant
with NK cells. We found signiﬁcant repopulation of T cells (36 	
17% vs 7	 2% control) in blood and thymus with evidence of B cell
reconstitution in bone marrow. NK cells can be used effectively as a
means of enhancing donor cell engraftment and in some circum-
stances inducing multilineage engraftment. This work was supported
by a grant from the NIH NIAID RO1 HL58842 (Table 1).
Engraftment (Percent) in Newborn Balb/c Recipients of B6 NK Cells
and Lin Bone Marrow at 8 Weeks
Groups
Animals
Engrafted
CD3
Cells Granulocytes B Cells Monocytes NK Cells
BM Alone 0/4 0.39  0.11 0.1  0.02 0.1  0.04 0.1  0.02
None
detected
NK  BM 7/10 16.5  6.3 0.5  0.7 2.6  1.0 1.4  1.8 2.1  0.6
NK Alone 3/10
None
detected
None
detected
None
detected
None
detected 5.11  1.4
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LONG TERM INFECTIOUS COMPLICATIONS FOLLOWING REDUCED IN-
TENSITY CONDITIONING (RIC) ALLOGENEIC HLA-IDENTICAL SIBLING
TRANSPLANTATION (ALLO-SCT)
Etienne, A.1; Mohty, M.1; Faucher, C.1; Ferrando, M.1; Benramdane,
R.1; Zandotti, C.2; Collet, L.1; Vey, N.1; Stoppa, A.M.1; Coso, D.1;
Viens, P.1; Gastaut, J.A.1; Blaise, D.1 1. Institut Paoli-Calmettes,
Marseille, France; 2. CHU Timone, Marseille, France.
We analyzed infections occurring beyond 6 months after allo-
SCT, in 81 consecutive pts who received a RIC prior to allo-SCT
from HLA-identical siblings: median age was 49 (18–63) years. 33
(41%), 34 (42%) and 14 (17%) pts had respectively a myeloid,
lymphoid or non-hematological malignancy. 62 pts (77%) had an
advanced disease with high risk clinical features precluding the use
of standard myeloablative allo-SCT. 21 pts (26%) BMT and 60
(74%) PBSCT. RIC consisted of ﬂudarabine and busulfan with
ATG (high dose: 20 (25%); low dose: 50 (62%)) or of low dose
irradiation-based RIC (N11, 13%). With 26 (9–68) months
follow-up, 67 pts (83%) experienced at least one infectious episode
beyond the ﬁrst six months after allo-SCT developing at a median
of 8 (6–34) months. 221 infectious episodes were observed, of
which 123 (56%) required hospitalization and systemic anti-micro-
bial therapy. 94 episodes (43%) could be documented (bacterial,
n28; viral, n56; fungal, n10). Documented infections were:
gram negative bacteria (16%), other bacteria (14%), CMV positive
antigenemia (17%), HSV (25%), VZV (15%), other viruses (3%),
aspergillus (4%), candida species (6%). 81% pts (n54) with an
infection were under systemic immunosuppressive therapy for
chronic GVHD. Moreover, 24 pts (30%) experienced 1 episode
of documented infections (median, 2 episodes; range, 1–12). In a
univariate analysis performed in the pts with documented infec-
tion, age 
50 (P0.06), the use of PBSCs as stem cell source
(P0.03) and a history of DLI (P0.002), exerted a protective
effect against infection occurrence. In a multivariate analysis, DLI
was signiﬁcantly associated with a decreased risk of long term
infections (P0.002; RR0.23; 95% CI, 0.1–0.6), indirectly high-
lighting the protective effect of donor origin immunity after allo-
SCT. In this series of pts surviving at least 6 months after RIC
allo-SCT, the overall long term transplant-related mortality was
14% (n11), of whom 6 deaths were attributed to infections (3
bacterial septicemia, 2 aspergillosis, 1 pneumocystosis), giving a
cumulative incidence of long term-infectious related mortality of
7% (95% CI, 1.4–12.6%). Obviously, prospective efforts to de-
velop optimal antimicrobial preventive strategies after RIC allo-
SCT are still needed. However, the results from this analysis
compare favorably with data from the standard myeloablative allo-
SCT setting.
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DRAMATIC CHANGE IN TREATMENT RELATED MORTALITY (TRM) FOR
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) DURING RECENT
YEARS. A ONE CENTRE ANALYSIS
Heilmann, C.; Laursen, H.B.; Muller, K.; Haastrup, E.; Jacobsen, N.
BMT Unit, Rigshospitalet, University Hospital, Copenhagen, Denmark.
Background: During recent years it has been the impression in
many centres that TRM following allogeneic stem cell transplants
has declined signiﬁcantly. This impression has been strong in our
centre as well. The aim of the present study was to analyze the
magnitude of this presumed reduction in procedure related risks
and to examine possible causes. Method: We analyzed a recent
time period of ten years from Jan. 1994 to Jan. 2003. Non my-
eloablative transplants were excluded from the study. During this
period 224 and 219 standard allotransplants were performed dur-
ing the ﬁrst and the second 5-year time periods respectively. All
transplants were performed at the same centre (Copenhagen, Den-
mark), whose organization has essentially remained the same for
the whole time period. Results: TRM differed signiﬁcantly
(p
0.0001) between the two time periods. The one-year Kaplan-
Meier based TRM declined from 33.5% to 13.9%. On the basis of
univariate analysis no signiﬁcant differences was found between the
compositions of the main diagnosis (AML, ALL, MDS, CML,
non-malignant). Likewise, when the pre-transplant stages of acute
leukaemia and CML were compared between the two periods non
differences were recorded, except that slightly less very high risk
ALL patients were transplanted during the last period. No differ-
ence in age distribution was found. In contrast, a tendency for a
more restrictive donor selection policy could be recorded. Hence,
the composition of donor types (HLA-id Sib vs. other fam. donors
vs. UD; p0.007), donor gender (less female to men; p0.018) and
the use of class I high-resolution donor typing for UD (p0.0001)
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